These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 15930295)

  • 61. Effects of potent vitamin D3 analogs on clonal proliferation of human prostate cancer cell lines.
    de Vos S; Holden S; Heber D; Elstner E; Binderup L; Uskokovic M; Rude B; Chen DL; Le J; Cho SK; Koeffler HP
    Prostate; 1997 May; 31(2):77-83. PubMed ID: 9140119
    [TBL] [Abstract][Full Text] [Related]  

  • 62. 1α,25-Dihydroxyvitamin D
    Ben-Eltriki M; Deb S; Guns EST
    J Steroid Biochem Mol Biol; 2021 May; 209():105828. PubMed ID: 33493594
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Gene expression profiling identifies a unique androgen-mediated inflammatory/immune signature and a PTEN (phosphatase and tensin homolog deleted on chromosome 10)-mediated apoptotic response specific to the rat ventral prostate.
    Desai KV; Michalowska AM; Kondaiah P; Ward JM; Shih JH; Green JE
    Mol Endocrinol; 2004 Dec; 18(12):2895-907. PubMed ID: 15358834
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells.
    Simboli-Campbell M; Narvaez CJ; van Weelden K; Tenniswood M; Welsh J
    Breast Cancer Res Treat; 1997 Jan; 42(1):31-41. PubMed ID: 9116316
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells.
    Torosyan Y; Simakova O; Naga S; Mezhevaya K; Leighton X; Diaz J; Huang W; Pollard H; Srivastava M
    Int J Cancer; 2009 Dec; 125(11):2528-39. PubMed ID: 19610065
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells.
    Qiao S; Pennanen P; Nazarova N; Lou YR; Tuohimaa P
    J Steroid Biochem Mol Biol; 2003 May; 85(1):1-8. PubMed ID: 12798352
    [TBL] [Abstract][Full Text] [Related]  

  • 67. 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration.
    Sung V; Feldman D
    Mol Cell Endocrinol; 2000 Jun; 164(1-2):133-43. PubMed ID: 11026565
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen.
    Vink-van Wijngaarden T; Pols HA; Buurman CJ; van den Bemd GJ; Dorssers LC; Birkenhäger JC; van Leeuwen JP
    Cancer Res; 1994 Nov; 54(21):5711-7. PubMed ID: 7923220
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CCAAT enhancer-binding protein alpha is a molecular target of 1,25-dihydroxyvitamin D3 in MCF-7 breast cancer cells.
    Dhawan P; Wieder R; Christakos S
    J Biol Chem; 2009 Jan; 284(5):3086-3095. PubMed ID: 19054766
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines.
    Stephen RL; Gustafsson MC; Jarvis M; Tatoud R; Marshall BR; Knight D; Ehrenborg E; Harris AL; Wolf CR; Palmer CN
    Cancer Res; 2004 May; 64(9):3162-70. PubMed ID: 15126355
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia.
    Abe J; Nakano T; Nishii Y; Matsumoto T; Ogata E; Ikeda K
    Endocrinology; 1991 Aug; 129(2):832-7. PubMed ID: 1855478
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prostate derived factor in human prostate cancer cells: gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth.
    Lambert JR; Kelly JA; Shim M; Huffer WE; Nordeen SK; Baek SJ; Eling TE; Lucia MS
    J Cell Physiol; 2006 Sep; 208(3):566-74. PubMed ID: 16741990
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype.
    Butterworth KT; McCarthy HO; Devlin A; Ming L; Robson T; McKeown SR; Worthington J
    Int J Cancer; 2008 Aug; 123(4):760-8. PubMed ID: 18512241
    [TBL] [Abstract][Full Text] [Related]  

  • 74. 24R,25-Dihydroxyvitamin D
    Verma A; Cohen DJ; Schwartz N; Muktipaty C; Koblinski JE; Boyan BD; Schwartz Z
    Biochim Biophys Acta Gen Subj; 2019 Oct; 1863(10):1498-1512. PubMed ID: 31125679
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Antiestrogenic effects of all-trans-retinoic acid and 1,25-dihydroxyvitamin D3 in breast cancer cells occur at the estrogen response element level but through different molecular mechanisms.
    Demirpence E; Balaguer P; Trousse F; Nicolas JC; Pons M; Gagne D
    Cancer Res; 1994 Mar; 54(6):1458-64. PubMed ID: 8137248
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Calcitrol (1alpha,25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells.
    Kaeding J; Bélanger J; Caron P; Verreault M; Bélanger A; Barbier O
    Mol Cancer Ther; 2008 Feb; 7(2):380-90. PubMed ID: 18281521
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Testicular synthesis and vitamin D action.
    Hofer D; Münzker J; Schwetz V; Ulbing M; Hutz K; Stiegler P; Zigeuner R; Pieber TR; Müller H; Obermayer-Pietsch B
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3766-73. PubMed ID: 24937537
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089.
    Vink-van Wijngaarden T; Pols HA; Buurman CJ; Birkenhäger JC; van Leeuwen JP
    Eur J Cancer; 1996 May; 32A(5):842-8. PubMed ID: 9081364
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Early gene expression during androgen-induced inhibition of proliferation of prostate cancer cells: a new suppressor candidate on chromosome 13, in the BRCA2-Rb1 locus.
    Geck P; Szelei J; Jimenez J; Sonnenschein C; Soto AM
    J Steroid Biochem Mol Biol; 1999 Jan; 68(1-2):41-50. PubMed ID: 10215036
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Expression of the CCAAT/enhancer-binding proteins C/EBPalpha, C/EBPbeta and C/EBPdelta in breast cancer: correlations with clinicopathologic parameters and cell-cycle regulatory proteins.
    Milde-Langosch K; Löning T; Bamberger AM
    Breast Cancer Res Treat; 2003 May; 79(2):175-85. PubMed ID: 12825852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.